Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia: A systematic review and meta-analysis

Abstract

Context: Atorvastatin is typically used in the treatment of dyslipidemia. However, the interest in using anti-obesity medications such as orlistat has grown rapidly as obesity is one of the variables associated with dyslipidemia. Aims: To synthesize the findings from previous studies published to date on the potential effects of atorvastatin and tetrahydrolipstatin (orlistat) on the levels of serum LDL. Methods: A systematic review and meta-analysis of research reports and RCTs about atorvastatin and orlistat on LDL levels from articles published in Medline, PubMed, and Scopus from 2012 to 2022 were conducted using PRISMA and RevMan 5.4 software. Results: From 9 final included articles, 6 focused on atorvastatin and 3 on orlistat. Five papers on atorvastatin reported a significant decrease in LDL level, whereas only 2 from orlistat papers. There is a significant decrease in LDL level associated with Atorvastatin treatment (p = 0.04, CI = 1.58, 56.81, I2 = 99%), but not with orlistat (p = 0.05, CI = 0.10, 17.69, I2 = 93%). Conclusions: Here, it is shown that atorvastatin instead of orlistat has a significant effect on decreasing LDL serum levels in dyslipidemia patients.

Keywords

• atorvastatin
• dyslipidemia
• obesity
• orlistat
• tetrahydrolipstatin